AbbVie's stock plummeted by 12% after its anti-psychotic drug, emraclidine, failed to meet primary endpoints in Phase II trials for schizophrenia treatment.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
AbbVie's stock plummeted by 12% after its anti-psychotic drug, emraclidine, failed to meet primary endpoints in Phase II trials for schizophrenia treatment.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
We are preparing, please wait
This content is only available for premium members. Please become a paid member to access.
Download AppCurrently, memberships can only be purchased through the app.